Search PubMed⌕ Search

Biomedical subjects

H Graber

Publications and source records attributed to H Graber.

At least 37 records · Page 2Linked to original sources
PubMed1988

The effect of ciprofloxacin on antipyrine metabolism.

The effect of multiple-dose ciprofloxacin on antipyrine metabolism was studied in patients suffering from bacterial infections. The patients were given antipyrine 15 mg/kg intravenously before and after ciprofloxacin treatment. The dosage of ciprofloxacin was 500 mg bd by mouth for 8-10 days. Blood samples were taken at 0, 2, 4, 6, 10 h. Antipyrine total clearance was significantly decreased after ciprofloxacin treatment (0.85 +/- 0.45 vs. 0.52 +/- 0.24 ml/min/kg): elimination rate constants for antipyrine were decreased in all patients after ciprofloxacin, whereas no change in volume of distribution was observed. The average half-life of antipyrine was increased from 9.45 +/- 3.74 h to 14.92 +/- 3.32 h. In two males with advanced chronic hepatic failure the antipyrine half-lives were extremely prolonged. Our results support the hypothesis that ciprofloxacin inhibits intrinsic hepatic drug-metabolizing capacity and may be a source of clinically important drug interactions, particularly in patients with liver disease.

Adult↗
PubMed1988

Pharmacokinetics of cefotaxime and desacetylcefotaxime in elderly patients.

This study was undertaken to determine the effect of age on the pharmacokinetics of cefotaxime and desacetylcefotaxime after intravenous administration of 1 g cefotaxime. 30 elderly patients suffering from acute infection were enrolled in the study. They were divided into 3 subgroups (group I aged 60 to 70 years, group II aged 71 to 80 years, group III aged over 80 years) with 5 men and 5 women in each. The elimination of cefotaxime in patients aged between 60 and 80 years was slightly slower than that in young people: elimination half-lives (in men and women, respectively) in group I were 1.2 and 1.58 hours, in group II, 1.45 and 1.57 hours and in group III, 2.56 and 2.59 hours. The change in elimination of desacetylcefotaxime was similar to that of cefotaxime, but less marked. The slower elimination of cefotaxime in patients over 80 years of age may allow reduction in the dose without jeopardizing the efficacy of therapy, whereas in patients under 80 years of age the normal dosage is required.

Age Factors↗
PubMed1985

Long-term intermittent netilmicin therapy of chronic pyelonephritis: a pharmacokinetic and clinical study.

A trial was conducted with long-term intermittent netilmicin therapy in six patients suffering from chronic pyelonephritis. Netilmicin was given in full dose for a period of 3-10 days (2-6 mg/kg/day), followed by 2 mg/kg doses once or twice weekly for 3-6 months. Individual doses were determined by computer based on the age, sex, lean body weight and serum creatinine concentrations of the patients. During the full-dose period of treatment netilmicin concentrations in serum were between 2 and 16 mg/l in serum and between 50 and 200 mg/l in urine. During intermittent treatment serum levels remained below 2 mg/l (except for 8-12 hours after dosing); in the urine concentrations were permanently in therapeutic ranges (150-4 mg/l). Renal tissue levels were simulated. Six to 12 months after long-term netilmicin treatment all patients are abacteriuric and free from symptoms. No auditory or renal toxic effects occurred.

Adult↗
PubMed1983

Microbiologic and clinical studies with cefuroxime.

The microbiologic and therapeutic efficacy of cefuroxime, a lactamase-stable cephalosporin, was studied. Of the 2532 bacterial isolates of clinical origin, 80-95% of the E. coli, indole-negative Proteus, Klebsiella-enterobacter, Staphylococcus aureus, and 72-74% of indole-positive Proteus and Streptococcus B haemolyticus strains were found susceptible to cefuroxime by the disc method. Forty-three bacterial infections of 36 patients were treated; most of them were critically or seriously ill at the start of treatment. Half of the patients had failed to respond to previous antibacterial therapy. Cefuroxime was administered in doses of 750 and 1500 mg, three times daily, for an average of 11 days (6-37 days). Ten patients received an aminoglycoside in addition to cefuroxime. Forty-one infections of 34 patients were cured, one relapsed, and one did not respond. The pathogen was identified in 36 infections; in 34 it was eradicated. Cefuroxime was well tolerated by all patients including one with penicillin allergy. No side effects occurred except local pain at the site of i.m. injections in two cases. It is concluded that cefuroxime has a high efficacy against resistant strains and an outstanding value in severe bacterial infections.

Adolescent↗
PubMed1983

Age-associated pharmacokinetic changes of metronidazole.

Serum concentration and urinary excretion of metronidazole were determined after p.o. administration of 500 mg to 15 young (20-25 years old) and 20 elderly (over 70) subjects. Serum levels were consistently higher and the AUCs were almost doubled in the aged group. One of the effects underlying the decrease in total clearance is the diminished renal excretion; however, the role of the reduction of distribution volume seems to be more important. Red cell binding of metronidazole significantly decreased in the aged group; this may also contribute to the reduction of distribution volume. Reduction of the standard dose of metronidazole by 30-40% is recommended in elderly patients.

Adult↗